Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in Japan for Adults with Late-onset Pompe Disease (LOPD) PRINCETON, N.J., and TOKYO, June 25, 2025 (GLOBE NEWSWIRE) -- Amicus ...

PRINCETON, N.J., and TOKYO, June 25, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Pombiliti ...

In the space of four days, the number of FDA-approved therapies for ultra-rare genetic disorder Niemann-Pick disease has gone from zero to two, transforming the prospects for patients.

View today's Actelion Ltd ADR Representing 1/4 stock price and latest ALIOY news and analysis. Create real-time notifications to follow any changes in the live stock price.

Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease: TA912: 15 August 2023: 15 August 2023: Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and ...

Find the latest Amicus Therapeutics, Inc. (FOLD) stock quote, history, news and other vital information to help you with your stock trading and investing.

Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease: TA912: 15 August 2023: 15 August 2023: Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and ...